Citigroup’s Intellia Therapeutics NTLA Stock Holding History

Citigroup’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,000	Closed	-$158K	–	5810
2023 Q3	$158K	Buy	+5,000	New	+$194K	﹤0.01%	3767
2022 Q4	–	Sell	-25,000	Closed	-$1.4M	–	5899
2022 Q3	$1.4M	Buy	+25,000	New	+$1.55M	﹤0.01%	2451
2020 Q2	–	Sell	-5,600	Closed	-$68K	–	7631
2020 Q1	$68K	Sell	5,600 -20,200	-78%	-$272K	﹤0.01%	5686
2019 Q4	$378K	Buy	25,800 +7,400	+40%	+$103K	﹤0.01%	4670
2019 Q3	$246K	Buy	18,400 +6,900	+60%	+$110K	﹤0.01%	4975
2019 Q2	$188K	Buy	11,500 +8,000	+229%	+$126K	﹤0.01%	5326
2019 Q1	$60K	Sell	3,500 -100	-3%	-$1.49K	﹤0.01%	6187
2018 Q4	$49K	Sell	3,600 -18,500	-84%	-$344K	﹤0.01%	6264
2018 Q3	$633K	Buy	22,100 +10,100	+84%	+$294K	﹤0.01%	3999
2018 Q2	$328K	Buy	12,000 +3,600	+43%	+$87.2K	﹤0.01%	4532
2018 Q1	$177K	Buy	+8,400	New	+$207K	﹤0.01%	5088

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Citigroup's NTLA Position: Q2 2026 in Review

Citigroup increased its Intellia Therapeutics (NTLA) stake by 535% in Q2 2026, buying an estimated $2.75M and bringing the position to 233,257 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

Citigroup first reported a position in NTLA in Q2 2016 and has held it in 40 quarters since. The position peaked at $24.6M in Q1 2022. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Citigroup held 233,257 shares of Intellia Therapeutics worth $3.95M as of Q2 2026.
Citigroup bought 196,500 Intellia Therapeutics shares in Q2 2026, an estimated $2.75M.
Intellia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2349 holding.
Citigroup first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 40 quarters since.
Citigroup's Intellia Therapeutics position peaked at $24.6M in Q1 2022.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.